Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Desano To Supply HIV Drugs To Viiv
by Jean-François Tremblay
July 13, 2015
| A version of this story appeared in
Volume 93, Issue 28
Viiv Healthcare has selected Shanghai’s Desano Pharmaceuticals as an additional supplier of dolutegravir, the active pharmaceutical ingredient (API) in the HIV drug Tivicay. Desano will supply the ingredient to Viiv for sale in China, where it is now under regulatory review, and other developing countries. Owned by GlaxoSmithKline, Pfizer, and Japan’s Shionogi, Viiv was launched in 2009 to focus on HIV. A major supplier of APIs for HIV drugs, Desano supplies generic drug firms such as Cipla that provide HIV treatments to African countries.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter